Cargando…

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment

PURPOSE: This was a prospective single-arm study to assess the efficacy and safety of intradetrusor injections of onabotulinum toxin-A in children with urinary incontinence associated with neurogenic detrusor overactivity due to myelomeningocele. All patients had failed the first-line treatment of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarcan, Tufan, Akbal, Cem, Şekerci, Çağri A., Top, Tuncay, Şimşek, Ferruh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988441/
https://www.ncbi.nlm.nih.gov/pubmed/24741419
http://dx.doi.org/10.4111/kju.2014.55.4.281
_version_ 1782312022071836672
author Tarcan, Tufan
Akbal, Cem
Şekerci, Çağri A.
Top, Tuncay
Şimşek, Ferruh
author_facet Tarcan, Tufan
Akbal, Cem
Şekerci, Çağri A.
Top, Tuncay
Şimşek, Ferruh
author_sort Tarcan, Tufan
collection PubMed
description PURPOSE: This was a prospective single-arm study to assess the efficacy and safety of intradetrusor injections of onabotulinum toxin-A in children with urinary incontinence associated with neurogenic detrusor overactivity due to myelomeningocele. All patients had failed the first-line treatment of a combination of oral antimuscarinics and intermittent catheterization. MATERIALS AND METHODS: The study group consisted of 31 children with myelomeningocele with a mean age of 7.95 years (range, 5-3 years) who were followed up for a mean of 29 weeks. The amount of onabotulinum toxin A injected was 10 U/kg with a maximal dose of 300 U. There were 20 to 30 injection sites with rigid cystoscopic guidance under general anesthesia. RESULTS: Thirty of 31 patients reported dryness between intermittent catheterization intervals. The mean reduction in maximum detrusor pressure and the mean increase in maximum cystometric capacity from baseline were 53% and 51.5%, respectively, 6 weeks after injection. We found a 324% increase in mean bladder compliance and a 57% increase in mean intermittent catheterization volumes. The mean duration of efficacy was 28 weeks with a single injection and 36 weeks for repeated injections (minimum, 16 weeks; maximum, 52 weeks). The mean time interval between repeated onabotulinum toxin-A injections was 7 months (maximum, 13 months). Intradetrusor injections of onabotulinum toxin-A were well tolerated. CONCLUSIONS: Onabotulinum toxin-A injections into the bladder wall provide a significant symptomatic and urodynamic improvement in children with neurogenic detrusor overactivity due to myelomeningocele who are on intermittent catheterization. The treatment seems to be safe and very well tolerated.
format Online
Article
Text
id pubmed-3988441
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Urological Association
record_format MEDLINE/PubMed
spelling pubmed-39884412014-04-16 Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment Tarcan, Tufan Akbal, Cem Şekerci, Çağri A. Top, Tuncay Şimşek, Ferruh Korean J Urol Original Article PURPOSE: This was a prospective single-arm study to assess the efficacy and safety of intradetrusor injections of onabotulinum toxin-A in children with urinary incontinence associated with neurogenic detrusor overactivity due to myelomeningocele. All patients had failed the first-line treatment of a combination of oral antimuscarinics and intermittent catheterization. MATERIALS AND METHODS: The study group consisted of 31 children with myelomeningocele with a mean age of 7.95 years (range, 5-3 years) who were followed up for a mean of 29 weeks. The amount of onabotulinum toxin A injected was 10 U/kg with a maximal dose of 300 U. There were 20 to 30 injection sites with rigid cystoscopic guidance under general anesthesia. RESULTS: Thirty of 31 patients reported dryness between intermittent catheterization intervals. The mean reduction in maximum detrusor pressure and the mean increase in maximum cystometric capacity from baseline were 53% and 51.5%, respectively, 6 weeks after injection. We found a 324% increase in mean bladder compliance and a 57% increase in mean intermittent catheterization volumes. The mean duration of efficacy was 28 weeks with a single injection and 36 weeks for repeated injections (minimum, 16 weeks; maximum, 52 weeks). The mean time interval between repeated onabotulinum toxin-A injections was 7 months (maximum, 13 months). Intradetrusor injections of onabotulinum toxin-A were well tolerated. CONCLUSIONS: Onabotulinum toxin-A injections into the bladder wall provide a significant symptomatic and urodynamic improvement in children with neurogenic detrusor overactivity due to myelomeningocele who are on intermittent catheterization. The treatment seems to be safe and very well tolerated. The Korean Urological Association 2014-04 2014-04-10 /pmc/articles/PMC3988441/ /pubmed/24741419 http://dx.doi.org/10.4111/kju.2014.55.4.281 Text en © The Korean Urological Association, 2014 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Tarcan, Tufan
Akbal, Cem
Şekerci, Çağri A.
Top, Tuncay
Şimşek, Ferruh
Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
title Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
title_full Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
title_fullStr Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
title_full_unstemmed Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
title_short Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
title_sort intradetrusor injections of onabotulinum toxin-a in children with urinary incontinence due to neurogenic detrusor overactivity refractory to antimuscarinic treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988441/
https://www.ncbi.nlm.nih.gov/pubmed/24741419
http://dx.doi.org/10.4111/kju.2014.55.4.281
work_keys_str_mv AT tarcantufan intradetrusorinjectionsofonabotulinumtoxinainchildrenwithurinaryincontinenceduetoneurogenicdetrusoroveractivityrefractorytoantimuscarinictreatment
AT akbalcem intradetrusorinjectionsofonabotulinumtoxinainchildrenwithurinaryincontinenceduetoneurogenicdetrusoroveractivityrefractorytoantimuscarinictreatment
AT sekercicagria intradetrusorinjectionsofonabotulinumtoxinainchildrenwithurinaryincontinenceduetoneurogenicdetrusoroveractivityrefractorytoantimuscarinictreatment
AT toptuncay intradetrusorinjectionsofonabotulinumtoxinainchildrenwithurinaryincontinenceduetoneurogenicdetrusoroveractivityrefractorytoantimuscarinictreatment
AT simsekferruh intradetrusorinjectionsofonabotulinumtoxinainchildrenwithurinaryincontinenceduetoneurogenicdetrusoroveractivityrefractorytoantimuscarinictreatment